Rexford Capital’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$684K Sell
4,798
-261
-5% -$39.6K 0.43% 69
2026
Q2
$793K Buy
5,059
+57
+1% +$8.54K 0.49% 60
2026
Q1
$764K Buy
5,002
+8
+0.2% +$1.23K 0.55% 55
2025
Q4
$689K Hold
4,994
– – 0.52% 56
2025
Q3
$640K Buy
4,994
+68
+1% +$8.3K 0.5% 62
2025
Q2
$596K Buy
+4,926
New +$555K 0.49% 63

Other funds holding NVS

Rexford Capital's NVS Position: Q3 2026 in Review

Rexford Capital reduced its Novartis (NVS) stake by 5.2% in Q3 2026, selling an estimated $39.6K and leaving 4,798 shares worth $684K. The position accounts for 0.43% of the portfolio, ranked #69.

Rexford Capital first reported a position in NVS in Q2 2025 and has held it in 6 quarters since. The position peaked at $793K in Q2 2026. 1,555 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Rexford Capital held 4,798 shares of Novartis worth $684K as of Q3 2026.
  • Rexford Capital sold 261 Novartis shares in Q3 2026, an estimated $39.6K.
  • Novartis made up 0.43% of Rexford Capital's portfolio in Q3 2026, its #69 holding.
  • Rexford Capital first reported a position in Novartis in Q2 2025 and has held it in 6 quarters since.
  • Rexford Capital's Novartis position peaked at $793K in Q2 2026.
  • 1,555 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Rexford Capital's 13F filing for Q3 2026, filed 13 Nov 2026.